In summary, we can conclude that iguratimod is a relatively new DMARD, primarily used to ameliorate RA via suppression of cytokines and immunoglobulins, i.e., IL-6, TNF-α, IL-17, and the NF-ƙB pathway. This evidence concerns the gene IL6 and rheumatoid arthritis.